The IgG4 subtype is predominant in patients with CIDP with anti-NF155 antibody positivity, but IgG3 and IgG1 take advantage of IgG4 in patients with CIDP with anti-NF186 antibody positivity (Ng et al., 2012; Querol et al., 2017; Kira et al., 2019). Here, IGHG3 is linked to chronic inflammatory demyelinating polyradiculoneuropathy.